ATE501144T1 - Triaza- und tetraaza-anthrazendionderivate, ihre herstellung und verwendung als pharmazeutika - Google Patents

Triaza- und tetraaza-anthrazendionderivate, ihre herstellung und verwendung als pharmazeutika

Info

Publication number
ATE501144T1
ATE501144T1 AT04726960T AT04726960T ATE501144T1 AT E501144 T1 ATE501144 T1 AT E501144T1 AT 04726960 T AT04726960 T AT 04726960T AT 04726960 T AT04726960 T AT 04726960T AT E501144 T1 ATE501144 T1 AT E501144T1
Authority
AT
Austria
Prior art keywords
alkyl
phenyl
triaza
tetraaza
pyridinyl
Prior art date
Application number
AT04726960T
Other languages
English (en)
Inventor
Andreas Weichert
Hartmut Strobel
Paulus Wohlfart
Marcel Patek
Martin Smrcina
Aleksandra Weichsel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE501144T1 publication Critical patent/ATE501144T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04726960T 2003-04-24 2004-04-13 Triaza- und tetraaza-anthrazendionderivate, ihre herstellung und verwendung als pharmazeutika ATE501144T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20030009286 EP1471066A1 (de) 2003-04-24 2003-04-24 Triaza- und Tetraaza-anthrazendionderivate, ihre Herstellung und Verwendung als Pharmazeutika
PCT/EP2004/003851 WO2004094425A1 (en) 2003-04-24 2004-04-13 Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE501144T1 true ATE501144T1 (de) 2011-03-15

Family

ID=32946872

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04726960T ATE501144T1 (de) 2003-04-24 2004-04-13 Triaza- und tetraaza-anthrazendionderivate, ihre herstellung und verwendung als pharmazeutika

Country Status (13)

Country Link
EP (2) EP1471066A1 (de)
JP (1) JP4603530B2 (de)
AT (1) ATE501144T1 (de)
AU (1) AU2004232456B2 (de)
BR (1) BRPI0409698A (de)
CA (1) CA2523196C (de)
DE (1) DE602004031734D1 (de)
DK (1) DK1641795T3 (de)
ES (1) ES2362658T3 (de)
IL (1) IL171500A (de)
MX (1) MXPA05011267A (de)
PT (1) PT1641795E (de)
WO (1) WO2004094425A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846410B1 (de) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydrochinazolinone als 5ht-modulatoren
EP1741708A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
EP1741709A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
EP1905764A1 (de) 2006-09-30 2008-04-02 Sanofi-Aventis Substituierte 2-Phenylbenzimidazole und ihre Verwendung als Pharmazeutika
EP1923062A1 (de) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazole und ihre Verwendung als Pharmazeutika
EP1942104A1 (de) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropancarbonsäureamide und deren pharmazeutische Verwendung
EP1939180A1 (de) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamide und ihre Verwendung als Arzneimittel für die Stimulation der Expression der endothelialen NO-Synthase
EP1939181A1 (de) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
EP1964841A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine und deren pharmazeutische Verwendung
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
JP2022548558A (ja) * 2019-09-11 2022-11-21 ソルヴェイ（ソシエテ アノニム） 置換シクロヘキサンカルボニトリルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas

Also Published As

Publication number Publication date
DE602004031734D1 (de) 2011-04-21
AU2004232456B2 (en) 2010-06-17
JP4603530B2 (ja) 2010-12-22
BRPI0409698A (pt) 2006-04-18
JP2006524197A (ja) 2006-10-26
PT1641795E (pt) 2011-05-18
CA2523196A1 (en) 2004-11-04
IL171500A (en) 2010-06-30
EP1471066A1 (de) 2004-10-27
DK1641795T3 (da) 2011-06-27
WO2004094425A1 (en) 2004-11-04
MXPA05011267A (es) 2006-05-25
ES2362658T3 (es) 2011-07-11
AU2004232456A1 (en) 2004-11-04
EP1641795B1 (de) 2011-03-09
EP1641795A1 (de) 2006-04-05
CA2523196C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
ATE501144T1 (de) Triaza- und tetraaza-anthrazendionderivate, ihre herstellung und verwendung als pharmazeutika
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
AU2018211975B2 (en) Modulators of estrogen receptor proteolysis and associated methods of use
US12180193B2 (en) Accelerating fibrosarcoma protein degrading compounds and associated methods of use
AU2004309279B2 (en) Thiazole derivative
AU2015320675B2 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2024229317A1 (en) Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
JP6080226B2 (ja) 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
RU2012131129A (ru) Соединения замещенного n-(1н-индазол-4-ил)имидазол[1,2-а]-3-карбоксамида как ингибиторы cfms
RU2008125068A (ru) Спироциклические соединения
JP2024522192A (ja) がんを処置するために使用され得る尿素誘導体
RS60536B1 (sr) Supstituisana pirazolo[1,5-a]piridin jedinjenja kao inhibitori ret kinaze
EA035049B1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
JP2013515070A5 (de)
JP2009516743A5 (de)
KR20080098070A (ko) 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
DK1921077T3 (en) Means for treating and / or preventing sleep disorders
AU2013218354A1 (en) Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as TBK1 and IKK inhibitors
JP2025538097A (ja) がんを処置するための方法
EA037598B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
KR20150023798A (ko) 항말라리아 제제로서의 피리미디논 유도체
CN116848107A (zh) 化合物及其作为pde4激活剂的用途
KR20230110510A (ko) 통합 스트레스 반응 경로의 조절제
JP2025538452A (ja) ９型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強
US20250388604A1 (en) Compounds and Their Use as PDE4 Activators

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1641795

Country of ref document: EP